Glenview Trust Co Acquires 536 Shares of Eli Lilly and Company $LLY

Glenview Trust Co lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 0.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 190,812 shares of the company’s stock after purchasing an additional 536 shares during the period. Eli Lilly and Company accounts for approximately 2.3% of Glenview Trust Co’s portfolio, making the stock its 8th biggest holding. Glenview Trust Co’s holdings in Eli Lilly and Company were worth $145,590,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Sumitomo Mitsui Financial Group Inc. bought a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $27,000. Evolution Wealth Management Inc. acquired a new position in Eli Lilly and Company during the 2nd quarter valued at $29,000. Steph & Co. boosted its holdings in Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after purchasing an additional 29 shares during the period. Financial Gravity Companies Inc. acquired a new stake in Eli Lilly and Company in the 2nd quarter worth $31,000. Finally, Bare Financial Services Inc increased its holdings in shares of Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 29 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $1,040.12 on Tuesday. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The business’s fifty day moving average price is $1,053.28 and its two-hundred day moving average price is $910.46. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The stock has a market capitalization of $981.21 billion, a price-to-earnings ratio of 45.32, a price-to-earnings-growth ratio of 1.21 and a beta of 0.39.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 30.15%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on LLY shares. BMO Capital Markets reiterated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Leerink Partners raised their price objective on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an “outperform” rating in a research report on Thursday, February 5th. Jefferies Financial Group lifted their price objective on Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Friday, December 19th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,218.88.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly announced a roughly $1 billion AI investment aimed at accelerating drug discovery and strengthening its pipeline beyond GLP‑1 drugs; analysts and retail investors view this as a structural growth lever that supports longer‑term revenue diversification and investor enthusiasm following the Q4 beat. Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery
• Positive Sentiment: Topline results from the Phase 3 LIBRETTO‑432 trial show Retevmo (selpercatinib) delivered a highly statistically significant and clinically meaningful improvement in event‑free survival as adjuvant therapy in early‑stage RET fusion‑positive NSCLC — a clear clinical win that expands Lilly’s oncology franchise and increases future revenue/pipeline value. Lilly’s Retevmo (selpercatinib) delivers substantial event-free survival benefit
• Positive Sentiment: Lilly has built about $1.5 billion of inventory of a weight‑loss pill ahead of a planned global launch this summer, signaling commercial readiness and management’s expectation of strong demand that could accelerate near‑term revenue growth. Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill
• Positive Sentiment: Coverage highlights Lilly’s strategic moves beyond GLP‑1s — including RNA cancer programs, AI‑enabled discovery and obesity R&D — which reduce single‑product risk and support a multi‑pillar growth narrative. Eli Lilly Expands Beyond GLP-1 With RNA Cancer AI And Obesity Bets
• Neutral Sentiment: Lilly will participate in TD Cowen’s Health Care Conference on March 2 (CFO Lucas Montarce to speak); investors will watch for management commentary and any updated guidance or details on commercialization plans. Lilly to participate in TD Cowen’s 46th Annual Health Care Conference

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.